journal article·2023-02-22

Exosome-Functionalized, Drug-Laden Bone Substitute along with an Antioxidant Herbal Membrane for Bone and Periosteum Regeneration in Bone Sarcoma

Sneha Gupta, Irfan Qayoom, Purva Gupta, Archita Gupta, Prerna Singh, Sneha Singh, Ashok Kumar

Publisher page

Abstract

Developing advanced methods for effective bone reconstructive strategies in case of critical bone defects caused by tumor resection, trauma, and other implant-related complications remains a challenging problem in orthopedics. In the clinical management of bone diseases, there is a paradigm shift in using local drugs at the injury site; however, the dead space created during the surgical debridement of necrotic bone and soft tissues (periosteum and underlying muscle) leads to ineffective bone formation, thereby leading to secondary complications, and thus calls for better regenerative approaches. In this study, we have utilized an exosome-functionalized doxorubicin-loaded biodegradable nanocement (NC)-based carrier along with a Cissus quadrangularis (CQ) extract-laden antioxidant herbal membrane for simultaneously managing the periosteum as well as bone formation in the tumor resection model of osteosarcoma. We initially evaluated the efficacy of scaffolds for in vitro mineralization and bone formation. To examine the in vivo effectiveness, we developed a human osteosarcoma cell line (Saos-2)-induced tumor xenograft model with a critical-sized bone defect. The findings revealed that doxorubicin released from NC was successful in killing the tumor cells and was present even after 30 days of implantation. Additionally, the incorporation of exosomes aided the bone formation, resulting in around a 2.6-fold increase in the bone volume compared to the empty group as evaluated by micro-CT. The herbal membrane assisted in the development of periosteum and mineralizing bone callous as validated through histological and immunofluorescence analysis. Thus, our findings describe a one-step biomaterial-based cell-free approach to regenerate bone in osteosarcoma and prevent further fracture due to the complete development of periosteum and lost bone.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Bone Tissue Engineering Materials · Extracellular vesicles in disease · Orthopaedic implants and arthroplasty

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Biological Sciences and Bioengineering, Indian Institute of Technology Kanpur, Kanpur 208016, India

Department of Bioengineering and Biotechnology, Birla Institute of Technology, Mesra, Ranchi 835215, Jharkhand, India

Centre for Environmental Sciences and Engineering, Indian Institute of Technology Kanpur, Kanpur 208016, India

The Mehta Family Centre for Engineering in Medicine, Indian Institute of Technology Kanpur, Kanpur 208016, India

Centre for Nanosciences, Indian Institute of Technology Kanpur, Kanpur 208016, UP, India

Centre of Excellence for Orthopedics and Prosthetics, Gangwal School of Medical Sciences and Technology, Indian Institute of Technology Kanpur, Kanpur 208016, India

Funding

Indian Council of Medical Research · Council??of??Scientific and Industrial Research, India · Indian Institute of Technology Kanpur · Department of Science and Technology, Ministry of Science and Technology · Department of Biotechnology , Ministry of Science and Technology · Ministry of Human Resource Development

References (34)

Show source-provided references
1. 10.1186/s40001-021-00593-910.1186/s40001-021-00593-9 ↗
2. 10.1038/s41571-021-00519-810.1038/s41571-021-00519-8 ↗
3. Broadhead M. L. · Osteosarcoma Biol. Behav. Mech. · 2017
4. 10.1007/s00590-017-2063-010.1007/s00590-017-2063-0 ↗
5. 10.1177/002203451350644510.1177/0022034513506445 ↗
6. 10.1002/adhm.20210021510.1002/adhm.202100215 ↗
7. 10.1007/s00264-016-3233-010.1007/s00264-016-3233-0 ↗
8. 10.3389/fbioe.2018.0010510.3389/fbioe.2018.00105 ↗
9. 10.1038/s41578-020-0204-210.1038/s41578-020-0204-2 ↗
10. 10.1177/155932581989270210.1177/1559325819892702 ↗
11. 10.1155/2020/218716910.1155/2020/2187169 ↗
12. 10.1007/s10561-020-09867-810.1007/s10561-020-09867-8 ↗
13. 10.3389/fbioe.2020.0101510.3389/fbioe.2020.01015 ↗
14. 10.1038/s41409-019-0616-z10.1038/s41409-019-0616-z ↗
15. 10.1021/acsabm.1c0031110.1021/acsabm.1c00311 ↗
16. 10.7150/thno.5257010.7150/thno.52570 ↗
17. 10.1080/07388551.2021.201003110.1080/07388551.2021.2010031 ↗
18. 10.6026/9732063001657910.6026/97320630016579 ↗
19. 10.1016/j.biopha.2020.11075410.1016/j.biopha.2020.110754 ↗
20. 10.1016/j.bioactmat.2021.01.00810.1016/j.bioactmat.2021.01.008 ↗
21. 10.3389/fmolb.2020.0013910.3389/fmolb.2020.00139 ↗
22. 10.1016/j.jconrel.2022.05.02710.1016/j.jconrel.2022.05.027 ↗
23. 10.1016/j.cej.2021.13249010.1016/j.cej.2021.132490 ↗
24. 10.1021/acs.biomac.1c0031910.1021/acs.biomac.1c00319 ↗
25. Jivrajani M. · Anticancer Res. · 2014 · 34 · 7177
26. 10.1016/j.jbo.2018.02.00410.1016/j.jbo.2018.02.004 ↗
27. 10.3892/ol.2018.943410.3892/ol.2018.9434 ↗
28. 10.1016/j.molmed.2009.08.00410.1016/j.molmed.2009.08.004 ↗
29. 10.1148/rg.30610552410.1148/rg.306105524 ↗
30. 10.1002/jbmr.214010.1002/jbmr.2140 ↗
31. 10.1007/s11033-018-4285-610.1007/s11033-018-4285-6 ↗
32. 10.1111/j.1365-2249.2005.02840.x10.1111/j.1365-2249.2005.02840.x ↗
33. 10.1097/MD.000000000001305110.1097/MD.0000000000013051 ↗
34. 10.1021/acs.biomac.9b0132710.1021/acs.biomac.9b01327 ↗